Kopran Limited — PPTs, 15-05-2025: Investor Presentation

1. Financial Highlights:

Kopran reported revenue of Rs. 623.59 Cr in FY25, nearly stable compared to Rs. 629.20 Cr in FY24. EBITDA slightly declined to Rs. 72.90 Cr with margins at 11.58%. Net profit dropped to Rs. 38.55 Cr from Rs. 50.96 Cr due to higher finance costs (Rs. 9.34 Cr) and depreciation (Rs. 15.59 Cr). Net worth stands at Rs. 518.35 Cr, while borrowings rose to Rs. 147.79 Cr, reflecting capacity expansion investments.

2. Strategic Initiatives & Growth Drivers:

R&D-led growth targeting niche, high-value APIs and intermediates continues. Capacity is being expanded with a new API and R&D facility at Panoli. Efforts to reduce reliance on China by developing in-house intermediates and streamlining processes are ongoing. Automation of formulation packing lines and prudent capital allocation aim to improve asset turnover and operational efficiency.

3. Business Developments:

No recent acquisitions or partnerships. Continued launches across API clusters like anti-diabetic, anti-infective, and sterile carbapenems. Formulations portfolio includes 100+ international-standard dosages, supporting a strong export presence.

4. Market Position & Competitive Advantage:

Kopran is a global pharma player with integrated API and formulation operations. It leads in Atenolol and Sterile Carbapenems manufacturing, backed by world-class accredited plants. Presence in 50+ countries and certifications including US FDA, EU GMP, MHRA UK, and Health Canada support access to regulated markets.

5. Investor Implications:

Topline growth is steady but margin pressures and profit decline underscore execution challenges amid rising costs. Strategic capacity expansion and self-reliance drive positive growth potential. Investors should monitor execution on expansions and cost controls to gauge sustainable profitability.